Increased Chemosensitivity via Targeting Testicular Nuclear Receptor 4 (TR4)-Oct4-Interleukin 1 Receptor Antagonist (IL1Ra) Axis in Prostate Cancer CD133+Stem/Progenitor Cells to Battle Prostate Cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Increased Chemosensitivity via Targeting Testicular Nuclear Receptor 4 (TR4)-Oct4-Interleukin 1 Receptor Antagonist (IL1Ra) Axis in Prostate Cancer CD133+Stem/Progenitor Cells to Battle Prostate Cancer
Authors
Keywords
-
Journal
JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 288, Issue 23, Pages 16476-16483
Publisher
American Society for Biochemistry & Molecular Biology (ASBMB)
Online
2013-04-23
DOI
10.1074/jbc.m112.448142
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Oct-4 is required for an antiapoptotic behavior of chemoresistant colorectal cancer cells enriched for cancer stem cells: Effects associated with STAT3/Survivin
- (2013) Kunming Wen et al. CANCER LETTERS
- A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer
- (2012) A. Heidenreich et al. ANNALS OF ONCOLOGY
- Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy
- (2012) C. N. Sternberg et al. ANNALS OF ONCOLOGY
- Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
- (2012) J. Mezynski et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cabazitaxel Plus Prednisone for Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel: Results from the German Compassionate-use Programme
- (2012) Axel Heidenreich et al. EUROPEAN UROLOGY
- Cabazitaxel in metastatic castration-resistant prostate cancer
- (2012) Timothy A Yap et al. Expert Review of Anticancer Therapy
- Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties
- (2012) Linlin Zhang et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial
- (2012) Nicholas D James et al. LANCET ONCOLOGY
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pathobiological Implications of the Expression of EGFR, pAkt, NF-κB and MIC-1 in Prostate Cancer Stem Cells and Their Progenies
- (2012) Murielle Mimeault et al. PLoS One
- Overcoming docetaxel resistance in prostate cancer: a perspective review
- (2012) Clara Hwang Therapeutic Advances in Medical Oncology
- Premature aging with impaired oxidative stress defense in mice lacking TR4
- (2011) Yi-Fen Lee et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Methylseleninic acid potentiates multiple types of cancer cells to ABT-737-induced apoptosis by targeting Mcl-1 and Bad
- (2011) Shutao Yin et al. APOPTOSIS
- Metformin Inhibits Nuclear Receptor TR4-Mediated Hepatic Stearoyl-CoA Desaturase 1 Gene Expression With Altered Insulin Sensitivity
- (2011) E. Kim et al. DIABETES
- Testicular Nuclear Receptor 4 (TR4) Regulates UV Light-induced Responses via Cockayne Syndrome B Protein-mediated Transcription-coupled DNA Repair
- (2011) Su Liu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Chemotherapy-Based Treatment for Castration-Resistant Prostate Cancer
- (2011) Bostjan Seruga et al. JOURNAL OF CLINICAL ONCOLOGY
- Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma
- (2011) Lo-Lin Tsai et al. JOURNAL OF ORAL PATHOLOGY & MEDICINE
- Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer: a review
- (2011) Giuseppe Colloca et al. MEDICAL ONCOLOGY
- Drug-Tolerant Cancer Cells Show Reduced Tumor-Initiating Capacity: Depletion of CD44+ Cells and Evidence for Epigenetic Mechanisms
- (2011) Hong Yan et al. PLoS One
- Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling
- (2011) Lu Gan et al. PROSTATE
- Phase II Evaluation of Early Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel Combined With Hormonal Therapy in Patients With High-risk Metastatic Prostate Adenocarcinoma: Southwest Oncology Group S0032
- (2011) David C. Smith et al. UROLOGY
- Normal and malignant epithelial cells with stem-like properties have an extended G2 cell cycle phase that is associated with apoptotic resistance
- (2010) Lisa J Harper et al. BMC CANCER
- Genomic profiling of tumor initiating prostatospheres
- (2010) Maria Duhagon et al. BMC GENOMICS
- Why not treat human cancer with interleukin-1 blockade?
- (2010) Charles A. Dinarello CANCER AND METASTASIS REVIEWS
- The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer
- (2010) Yohann Loriot et al. EUROPEAN JOURNAL OF CANCER
- Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway
- (2010) Xiao Qi Wang et al. HEPATOLOGY
- Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1
- (2010) Te Liu et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Effective enrichment of prostate cancer stem cells from spheres in a suspension culture system
- (2010) Xinlan Fan et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer
- (2010) Christoph W. M. Reuter et al. WORLD JOURNAL OF UROLOGY
- Targeting the Mechanisms of Resistance to Chemotherapy and Radiotherapy with the Cancer Stem Cell Hypothesis
- (2010) Ryan Morrison et al. Journal of Oncology
- Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature
- (2009) George J. Klarmann et al. CLINICAL & EXPERIMENTAL METASTASIS
- Roles of Testicular Orphan Nuclear Receptors 2 and 4 in Early Embryonic Development and Embryonic Stem Cells
- (2009) Chih-Rong Shyr et al. ENDOCRINOLOGY
- Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer
- (2009) Akihiro Matsumoto et al. INTERNATIONAL JOURNAL OF UROLOGY
- Phase I Study of Ixabepilone, Mitoxantrone, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy: A Study of the Department of Defense Prostate Cancer Clinical Trials Consortium
- (2009) Jonathan E. Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: An integrated molecular profiling approach
- (2009) Brian T. Kawasaki et al. PROSTATE
- Cancer stem cell epigenetics and chemoresistance
- (2009) Francesco Crea et al. Epigenomics
- Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer
- (2008) Mari Nakabayashi et al. BJU INTERNATIONAL
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
- (2008) Dominik R. Berthold et al. JOURNAL OF CLINICAL ONCOLOGY
- Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone
- (2008) Orazio Caffo et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel
- (2007) Robert W. Ross et al. CANCER
- Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer
- (2007) Tomasz M. Beer et al. CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started